FDA Adds Warning to Zanaflex Label
Coadministering Zanaflex with CYP1A2 inhibitors could increase its sedative effects
FRIDAY, April 13 (HealthDay News) -- The U.S. Food and Drug Administration has changed the label for the spasticity drug Zanaflex (tizanidine hydrochloride) to warn that its use is contraindicated in patients taking fluvoxamine, ciprofloxacin or other CYP1A2 inhibitors due to a potentially dangerous increase in the risk of sedation and hypotension.
"Although there are no clinical studies evaluating the effects of other CYP1A2 inhibitors on tizanidine, coadministration of tizanidine with other CYP1A2 inhibitors (zileuton, other fluroquinolones, antiarrythmics, cimetidine, famotidine, oral contraceptives, acyclovir and ticlopidine) should be avoided," the FDA cautions.
Zanaflex is made by Acorda Therapeutics.